Nafamostat mesylate is under clinical development by Ensysce Biosciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase I drugs for Coronavirus Disease 2019 (COVID-19) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Nafamostat mesylate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Nafamostat mesylate overview
Nafamostat mesylate is under development for the treatment of coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other pulmonary diseases such as cystic fibrosis. It is administered by oral and inhalational route. It acts by targeting transmembrane protease serine 2 (TMPRSS2).
Ensysce Biosciences overview
Ensysce Biosciences is a clinical stage pharmaceutical company that develops solutions for severe pain relief. Its pipeline products include PF614 which treats pain with abuse protection; PF614 – MPAR treats pain with overdose protection; PF329 for pain with abuse protection; PF8001 and PF8026 treats attention-deficit or hyperactivity disorder (ADHD); PF9001 which treats opioid use disorder; Nafamostat for infectious diseases. The company’s platforms include Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) which treats pain and central nervous system disorders. It provides its products and services to the healthcare, medical and pharmaceutical sectors. Ensysce Biosciences is headquartered in San Diego, California, the US.
For a complete picture of Nafamostat mesylate’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
